Invitrogen Strengthens Global Management Team; Appoints Experienced Executives to Improve Operations
Invitrogen Corp., a provider of essential life science technologies for disease research and drug discovery, announced the appointments of Karen Gibson, senior vice president of information technology and chief information officer, and Nicolas Barthelemy to the position of senior vice president of global operations. Gibson will focus on implementing global information technology (IT) programs, and Barthelemy will concentrate on improving Invitrogen’s resources for streamlining global operations to increase quality and value to customers.
“It is critical in the 21st century for a technology-based company to have a strong information technology platform with an even stronger operational infrastructure behind it,” said Gregory T. Lucier, Invitrogen’s president and CEO. “At Invitrogen, we see our global operations and information technology functions as agents for accelerating our success with clients.”
Gibson brings to Invitrogen proven global leadership coupled with an extensive technical background. Most recently, she was vice president of Global eBusiness and chief information officer for General Electric’s Medical Systems Information Technologies division. In this executive leadership role, Gibson led an organization of more than 100 associates in 12 locations spanning seven countries. Gibson also worked as a Director of IT for Quantum Health Resources and Ethicon Endo-Surgery (a Johnson & Johnson Company). She holds a B.S. in Computer Technology from Purdue University and an MBA from Ohio University.
Barthelemy brings to Invitrogen’s senior management a unique combination of international experience and cross-functional skills in the biotech and pharmaceutical industries. Most recently, he was vice president of manufacturing and general manager of the Research Triangle Park site for Biogen Inc., a global leader in the development, manufacturing and commercialization of novel biologic therapies. In this executive leadership role, Barthelemy increased operational efficiencies and established systems that resulted in a world-class quality manufacturing organization. Prior to that, he worked in a variety of domestic and international executive roles at Biogen. Barthelemy holds a combined degree in math, physics and chemistry from Ecole Sainte Genevieve and went on to earn a Masters of Science degree in Chemistry from the Ecole Superieure de Physiques et Chimie Industrielles, both located in France. He later attended the University of California at Berkley to earn a Masters of Science in Chemical Engineering. He also completed the Program for Management Development at Harvard Business School.
Both executives expressed their excitement to join a company that demonstrates a high level of passion and servitude to the global life sciences community.
“Invitrogen provides critical information to researchers around the world through its tools, informatics and industry-recognized Web site,” stated Gibson. “I plan to build on this foundation and create an even more compelling information capability both for clients and employees.”
“Making sure we are meeting our customers needs in the most efficient means possible is the key to maintaining the high level of trust we enjoy in our industry,” added Barthelemy. “My goal is to help Invitrogen continue its strong quality reputation by introducing techniques like Lean and Six Sigma into our operations.”
These positions will report directly to Lucier and are effective immediately.
About Invitrogen
Invitrogen Corp. (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bio-production. Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bio-informatics and cell biology — placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen has headquarters in Carlsbad, Calif. and conducts business in more than 70 countries around the world. The company globally employs approximately 3,800 scientists and other professionals. For more information about Invitrogen visit the company’s Web site at www.invitrogen.com .
Safe Harbor Statement
Certain statements contained in this press release are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) The appointments of Gibson and Barthelemy will increase the quality and value of products and services to Invitrogen’s customers; 2) Global operations and information technology will accelerate product development; 3) Gibson’s role will create a more compelling information capability for clients and employees; 4) Barthelemy’s role will introduce Six Sigma and Lean into Invitrogen’s operations. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks:
a) Gibson and Barthelemy’s appointments may not impact the quality or value of Invitrogen’s offerings; b) Global operations and information technology will have no significant impact on product development; c) Invitrogen’s information capability may not change as a result of Gibson’s appointment; and d) Invitrogen may choose not to pursue programs such as Six Sigma or Lean, as well as other risks and uncertainties detailed from time to time in Invitrogen’s Securities and Exchange Commission filings.
Contact:
Invitrogen Corp., Carlsbad
Greg Geissman, 760-476-7032
gregory.geissman@invitrogen.com
